Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies
Jerry R. Greenfield, Ruth Frampton, Jennifer R. Snaith. Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies. // Diabetes, Obesity and Metabolism. – 2026. – DOI: 10.1111/dom.71505. – URL: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71505?af=R
Jerry R. Greenfield, Ruth Frampton, & Jennifer R. Snaith (2026). Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71505
Jerry R. Greenfield, et al. “Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies.” Diabetes, Obesity and Metabolism, 2026. doi:10.1111/dom.71505.
@article{Greenfield2026,
title = {Glucagon‐Like Peptide‐1 Receptor Agonists in Type 1 Diabetes: The Importance of Identifying the Insulin‐Resistant Type 1 Diabetes Phenotype, and Differentiating Early and Newer Generation Therapies},
author = {Greenfield, Jerry R. and Frampton, Ruth and Snaith, Jennifer R.},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71505},
url = {https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71505?af=R}
}